Anthem Biosciences IPO Allotment: The IPO of Anthem Biosciences is now heading toward its next big step and that is ‘share allotment’, which is expected to be finalised today, July 17.
Founded in 2006, Anthem Biosciences operates as a full-stack Contract Research, Development, and Manufacturing Organization (CRDMO), supporting drug discovery to manufacturing for biotech startups and large pharmaceutical players globally.
Anthem Biosciences IPO Allotment Expected Date: Here's how to check the allotment status online
Anthem Biosciences IPO Allotment Live: Subscription recap
Anthem Biosciences’ IPO attracted strong investor interest across categories, closing with an overall subscription of approximately 63.86 times. The bulk of the demand came from Qualified Institutional Buyers (QIBs), who subscribed 182.65 times their allotted quota. Non-Institutional Investors (NIIs) also showed participation with a subscription of 42.36 times. Meanwhile, retail investors subscribed 5.64 times.
Anthem Biosciences IPO Allotment Live: Mehta Equities on ABL
“We believe Anthem Biosciences IPO brings investors an opportunity to invest in the high-growth CRDMO space, uniquely positioned with fully integrated capabilities across small and large molecules, including NCE and NBE platforms—a rarity in India. We think with a strong track record of 8,000+ projects, deep engagement with 675+ clients, and a robust pipeline of 242 active projects, Anthem has demonstrated sustained innovation through early adoption of advanced modalities like ADC, RNAi, and flow chemistry, and a leadership position in green chemistry," said Rajan Shinde, Research Analyst with Mehta Equities.
Anthem Biosciences IPO Allotment Live: IPO dates and timeline
The initial public offering (IPO) of Anthem Biosciences followed a structured timeline, beginning with the subscription window opening on July 14, and closing just two days later on July 16. The allotment of shares is expected to be finalised today July 17, giving investors a quick turnaround. Those who do not receive allotment can expect refunds or credit of shares in their demat accounts by July 18. The company is set to make its stock market debut on July 21, when its shares will be listed on both the NSE and BSE.
Anthem Biosciences IPO Allotment Live: Motilal Oswal on ABL IPO
"We recommend investors to ‘Subscribe’ to the issue. At Rs 570, the issue is priced at 71x FY25 P/E as compared to the listed peers' average of 95x. Anthem Biosciences, the only CRDMO in India with robust capabilities in both small molecules and biologics. Given the strong industry tailwinds, ABL is well-positioned to capitalise on market opportunities through its capacity expansion. We favour ABL for its strong financial performance, expanding global client base, and industry-leading metrics," said Motilal Oswal in an IPO note.
Anthem Biosciences IPO Allotment Live: Issue details
Anthem Biosciences IPO is a fully offer-for-sale (OFS) issue, with no fresh equity being raised. The company is looking to offload around 5.96 crore shares through this book-built issue. The total issue size is estimated to be approximately Rs 3,395 crore. Each share carries a face value of Rs 2. The IPO structure means the proceeds will go to the selling shareholders rather than the company itself.
Anthem Biosciences IPO Allotment Live: Company overview
Anthem Biosciences, headquartered in Bengaluru, is a Contract Research, Development, and Manufacturing Organization (CRDMO) established in 2006. The company offers a wide range of services across drug discovery, development, and manufacturing, catering to a broad client base that includes biotech startups as well as established pharmaceutical companies.
Its operations span across 44 countries, with a focus on fermentation-based Active Pharmaceutical Ingredients (APIs), biosimilars, peptides, enzymes, and nutritional actives. Anthem Biosciences plays a role in supporting global pharmaceutical and biotech supply chains through its integrated research and production capabilities.